Genetic polymorphism CYP2C19 and its relation to pharmacokinetics and acid-suppression effect of proton pump inhibitors

被引：0
作者：
Niu, CY
Luo, JY
机构：
来源：
GASTROENTEROLOGY | 2004年 / 126卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A536 / A536
页数：1
相关论文
共 50 条
  • [1] Relationship between the acid-suppression efficacy of proton pump inhibitors and CYP2C19 genetic polymorphism in patients with peptic ulcer
    牛春燕
    罗金燕
    木尼拉
    王学勤
    Journal of Pharmaceutical Analysis, 2008, (03) : 213 - 217
  • [2] Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors
    Chaudhry, A. S.
    Kochhar, R.
    Kohli, K. K.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2008, 127 (06) : 521 - 530
  • [3] Impact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors
    Mazer-Amirshahi, Maryann
    van den Anker, John
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03) : 359 - 359
  • [4] Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole
    Cho, Hoon
    Choi, Min-Koo
    Cho, Doo-Yeon
    Yeo, Chang-Woo
    Jeong, Hye-Eun
    Shon, Ji-Hong
    Lee, Jun-Yeoun
    Shin, Jae-Soo
    Cho, Mong
    Kim, Dong-Yeon
    Shin, Jae-Gook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (07) : 976 - 984
  • [5] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    Wang, JH
    Liu, ZQ
    Wang, W
    Chen, XP
    Shu, Y
    He, N
    Zhou, HH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 42 - 47
  • [6] Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19
    Yu, BN
    Chen, GL
    He, N
    Ouyang, DS
    Chen, XP
    Liu, ZQ
    Zhou, HH
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (10) : 1255 - 1259
  • [7] Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype
    Qiao, HL
    Hu, YR
    Tian, X
    Jia, LJ
    Gao, N
    Zhang, LR
    Guo, YZ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (02) : 107 - 112
  • [8] Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype
    Hai-Ling Qiao
    Yu-Rong Hu
    Xin Tian
    Lin-Jing Jia
    Na Gao
    Li-Rong Zhang
    Yu-Zhong Guo
    European Journal of Clinical Pharmacology, 2006, 62 : 107 - 112
  • [9] Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
    Mafuru, Magesa
    Wu, Sanlan
    Mayala, Henry
    Msengwa, Zaituni
    Phillip, Amani
    Mgone, Charles
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1379 - 1389
  • [10] Reply to: Letter to the Editor "Impact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors"
    Jiang, Fen
    Shin, Jae-Gook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03) : 360 - 360
12345